The president is jettisoning the GOP’s corporate allies in a bid to inoculate his party from voters stressed by the cost of ...

Researchers in Indianapolis are launching a first-of-its-kind study when it comes to GLP-1 drugs and the impact on the ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S.

-- The Food and Drug Administration has extended its review of Eli Lilly's oral weight-loss drug orfoglipron, Reuters reported Thursday, citing internal FDA documents. -- A decision on the drug's ...

Eli Lilly (LLY) shares slipped ~5% on Thursday, marking what could be its biggest intraday loss in five months after Reuters ...

Delaware Attorney General Kathy Jennings filed a lawsuit Jan. 14 against three drugmakers and three pharmacy benefit managers, alleging they conspired to inflate insulin prices by up to 1,000% over 15 ...

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

Eli Lilly & Co. has disclosed new glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of obesity and type 2 diabetes.